44 related articles for article (PubMed ID: 12747749)
1. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.
Makki A; Weidt G; Blachere NE; Lefrançois L; Srivastava PK
Cancer Immun; 2002 Apr; 2():4. PubMed ID: 12747749
[TBL] [Abstract][Full Text] [Related]
2. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.
Llopiz D; Dotor J; Zabaleta A; Lasarte JJ; Prieto J; Borrás-Cuesta F; Sarobe P
Cancer Immunol Immunother; 2008 Jan; 57(1):19-29. PubMed ID: 17564702
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity.
Kim KW; Kim SH; Jang JH; Lee EY; Park SW; Um JH; Lee YJ; Lee CH; Yoon S; Seo SY; Jeong MH; Lee ST; Chung BS; Kang CD
Cancer Immunol Immunother; 2004 Apr; 53(4):315-22. PubMed ID: 14685778
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice.
Johnston D; Reynolds SR; Bystryn JC
Cancer Immunol Immunother; 2006 Apr; 55(4):412-9. PubMed ID: 16151809
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous elicitation of potent antitumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-beta II receptor without active antigen-sensitization.
Kontani K; Kajino K; Huangi CL; Fujino S; Taguchi O; Yamauchi A; Yokomise H; Ogasawara K
Cancer Immunol Immunother; 2006 May; 55(5):579-87. PubMed ID: 16032398
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy against antigenic tumors: a game with a lot of players.
Pérez-Díez A; Marincola FM
Cell Mol Life Sci; 2002 Feb; 59(2):230-40. PubMed ID: 11915941
[TBL] [Abstract][Full Text] [Related]
7. A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells.
Wang H; Wu X; Sun Y; Liu A; He Y; Xu Z; Lu Y; Zhan C
J Control Release; 2024 Apr; 368():208-218. PubMed ID: 38395156
[TBL] [Abstract][Full Text] [Related]
8. Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.
Alpizar YA; Chain B; Collins MK; Greenwood J; Katz D; Stauss HJ; Mitchison NA
Cancer Immunol Immunother; 2011 Aug; 60(8):1127-35. PubMed ID: 21479639
[TBL] [Abstract][Full Text] [Related]
9. The G7 Summit 2021: time for our world leaders to step up to the challenge of antimicrobial resistance.
Joshi LT
Access Microbiol; 2021; 3(12):000298. PubMed ID: 35024558
[No Abstract] [Full Text] [Related]
10. Using a Prime-Boost Vaccination Strategy That Proved Effective for High Resolution Epitope Mapping to Characterize the Elusive Immunogenicity of Survivin.
Mould RC; van Vloten JP; AuYeung AWK; Walsh SR; de Jong J; Susta L; Mutsaers AJ; Petrik JJ; Wood GA; Wootton SK; Karimi K; Bridle BW
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944889
[TBL] [Abstract][Full Text] [Related]
11. Simulated microgravity-mediated reversion of murine lymphoma immune evasion.
Bradley JH; Barwick S; Horn GQ; Ullrich E; Best B; Arnold JP; Gregg RK
Sci Rep; 2019 Oct; 9(1):14623. PubMed ID: 31602007
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo.
Jackaman C; Majewski D; Fox SA; Nowak AK; Nelson DJ
Cancer Immunol Immunother; 2012 Dec; 61(12):2343-56. PubMed ID: 22714286
[TBL] [Abstract][Full Text] [Related]
13. Theoretical aspects of immunity.
Deem MW; Hejazi P
Annu Rev Chem Biomol Eng; 2010; 1():247-76. PubMed ID: 22432581
[TBL] [Abstract][Full Text] [Related]
14. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.
Mkrtichyan M; Ghochikyan A; Davtyan H; Movsesyan N; Loukinov D; Lobanenkov V; Cribbs DH; Laust AK; Nelson EL; Agadjanyan MG
Cell Immunol; 2011; 270(2):188-97. PubMed ID: 21641588
[TBL] [Abstract][Full Text] [Related]
15. Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design.
Kmieciak M; Morales JK; Morales J; Bolesta E; Grimes M; Manjili MH
Cancer Immunol Immunother; 2008 Sep; 57(9):1391-8. PubMed ID: 18278493
[TBL] [Abstract][Full Text] [Related]
16. Design and pre-clinical evaluation of a universal HIV-1 vaccine.
Létourneau S; Im EJ; Mashishi T; Brereton C; Bridgeman A; Yang H; Dorrell L; Dong T; Korber B; McMichael AJ; Hanke T
PLoS One; 2007 Oct; 2(10):e984. PubMed ID: 17912361
[TBL] [Abstract][Full Text] [Related]
17. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.
Ghochikyan A; Mkrtichyan M; Loukinov D; Mamikonyan G; Pack SD; Movsesyan N; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG
J Immunol; 2007 Jan; 178(1):566-73. PubMed ID: 17182597
[TBL] [Abstract][Full Text] [Related]
18. Sculpting the immunological response to dengue fever by polytopic vaccination.
Zhou H; Deem MW
Vaccine; 2006 Mar; 24(14):2451-9. PubMed ID: 16417956
[TBL] [Abstract][Full Text] [Related]
19. Adoptive T cell therapy: Addressing challenges in cancer immunotherapy.
Yee C
J Transl Med; 2005 Apr; 3(1):17. PubMed ID: 15860133
[TBL] [Abstract][Full Text] [Related]
20. CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.
Gnjatic S; Jäger E; Chen W; Altorki NK; Matsuo M; Lee SY; Chen Q; Nagata Y; Atanackovic D; Chen YT; Ritter G; Cebon J; Knuth A; Old LJ
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11813-8. PubMed ID: 12186971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
